These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27156362)

  • 1. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
    Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
    Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
    Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
    Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.
    Yalcin Gungoren E; Yorgun Altunbas M; Dikici U; Meric Z; Eser Simsek I; Kiykim A; Can S; Karabiber E; Yakici N; Orhan F; Cokugras H; Aydogan M; Ozdemir O; Bilgic Eltan S; Baris S; Ozen A; Karakoc-Aydiner E
    J Clin Immunol; 2024 Aug; 44(8):169. PubMed ID: 39098942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
    Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
    Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
    Agostini C; Blau IW; Kimby E; Plesner T
    Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
    Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
    Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
    Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
    Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
    Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
    Front Immunol; 2021; 12():670547. PubMed ID: 34012453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
    Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
    J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
    Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
    Front Immunol; 2020; 11():981. PubMed ID: 32670265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
    Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
    Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous and subcutaneous immunoglobulin G replacement therapy.
    Bonilla FA
    Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
    Shah N; Mustafa SS; Vinh DC
    Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
    Wasserman RL
    Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
    Rubinstein A; Mabudian M; McNeil D; Patel NC; Wasserman RL; Gupta S; Carrasco P; Chen J; Garcia E; Nagy A; Yel L
    J Clin Immunol; 2024 Aug; 44(8):181. PubMed ID: 39158670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.